KR890009925A - 헤테로사이클릭-치환된 퀴놀린 카복실산 - Google Patents

헤테로사이클릭-치환된 퀴놀린 카복실산 Download PDF

Info

Publication number
KR890009925A
KR890009925A KR1019880016841A KR880016841A KR890009925A KR 890009925 A KR890009925 A KR 890009925A KR 1019880016841 A KR1019880016841 A KR 1019880016841A KR 880016841 A KR880016841 A KR 880016841A KR 890009925 A KR890009925 A KR 890009925A
Authority
KR
South Korea
Prior art keywords
fluoro
carboxylic acid
dihydro
oxo
tetrahydro
Prior art date
Application number
KR1019880016841A
Other languages
English (en)
Other versions
KR900008568B1 (ko
Inventor
엘리자베스 브라이티 카데린
3세 존 애담스 로웨
로버트 맥과이어크 폴
Original Assignee
알렌 제이.스피겔
화이자 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알렌 제이.스피겔, 화이자 인코포레이티드 filed Critical 알렌 제이.스피겔
Publication of KR890009925A publication Critical patent/KR890009925A/ko
Application granted granted Critical
Publication of KR900008568B1 publication Critical patent/KR900008568B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Quinoline Compounds (AREA)

Abstract

내용 없음

Description

헤테로사이클릭-치환된 퀴놀린 카복실산
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (9)

  1. 하기 일반식(Ⅰ)의 화합물 또는 약제학적으로 허용되는 이들의 산부가염.
    상기식에서, Y는 각각 독립적으로 (C1-C3)알킬, 비닐, (C1-C3)하이드록시알킬, 비닐, (C1-C3)할로알킬(여기에서, 할로는 플루오로 또는 클로로이다). 사이클로프로필, O,P-디플루오로 또는 P-플루오로페닐이고, A는 독립적으로 C-H, C-F, C-Cl, C-OCH3, 또는 N이거나 A는 탄소이고, A와 Y는 함께 일반식 C-Z-CH2-또는 C-Z-CH2 의 그룹[여기에서, Z는 산소 또는 CH2이고, R3는 수소, (C1-C3)-알킬, 또는 할로메틸(여기에서, 할로는 플루오로 또는 클로로이다)이다]을 형성하고 ; R1은 하이드록시, (C1-C6)알콕시, 아미노, (C1-C6)-알킬아미노, 또는 OM(여기에서, M은 약제학적으로 허용되는 양이온이다)이고 ; R2는
    [여기에서, Q는 O,S 또는 NH이고, X는 수소이거나 하나 또는 두개의 CH2NHR4,NHR4또는 (C1-C6)알킬설포닐 (여기에서, R4는 수소 또는 (C1-C6)알킬이다)이며, R5는 수소, (C1-C5)-알킬, 하이드록시, 아미노, 아미노(C1-C4)알킬, 디(C1-C4)알킬아미노, (C1-C4)알킬아미노, (C1-C4)-알킬아미노(C1-C4)알킬, 페닐아미노, 피리딜 아미노 또는 (H2N)2=N이고, O는 1이고, m은 1 또는 2이거나, P는 2이고 m이 1이며 n은 0또는 1이다]이다.
  2. 제1항에 있어서, R1이 하이드록시임을 특징으로 하는 화합물.
  3. 제1항 또는 제2항에 있어서, A가 C-H임을 특징으로 하는 화합물.
  4. 제1항 내지 제3항의 어느 한항에 있어서, R2가 6-[5,6,7,8-테트라하이드로-1,6-나프티리딘]임을 특징으로 하는 화합물.
  5. 제1항 또는 제2항에 있어서, R2가 5-(2-R5-치환된 4,5,6,7-테트라하이드로티아졸로[5,4-c]피리딜)이고 R5가 제1항에서 정의된 바와같음을 특징으로 하는 화합물.
  6. 제5항에 있어서, R5가 아미노 또는 3-피리딜임을 특징으로 하는 화합물.
  7. 제1항에 있어서, 상기 화합물이 7-[5-(2-아미노-4,5,6,7-테트라하이드로티아졸로[5,4-c]피리딜)]-1-에틸-6-플루오로-1,4-디하이드로-4-옥소-퀴놀린-3-카복실산, 7-[5-(2-아미노-4,5,6,7-테트라하이드로티아졸로[5,4-c]피리딜)]-1-사이클로프로필-6-플루오로-1,4-디하이드로-4-옥소-퀴놀린-3-카복실산, 1-사이클로프로필-6-플루오로-1,4-디하이드로-4-옥소-7-[5-(2-아미노-4,5,6,7-테트라하이드로티아졸로[5,4-c]피리딜)]-퀴놀린-3-카복실산, 1-사이클로프로필-6-플루오로-1,4-디하이드로-7-[5-(2-(3-피리딜)아미노-4,5,6,7-테트라하이드로티아졸로[5,4-c]피리딜)]-4-옥소-퀴놀린-3-카복실산, 1-에틸-6-플루오로-1,4-디하이드로-4-옥소-7-[6-(5,6,7,8-테트라하이드로-1,6-나프티리딘)]-퀴놀린-3-카복실산, 1-사이클로프로필-6-플루오로-1,4-디하이드로-4-옥소-7-[6-(5,6,7,8-테트라하이드로-1,6-나프티리딘)]-1,8-니프티리딘-3-카복실산, 7-6[6-(5,6,7,8-테트라하이드로-1,6-나프티리딘)]-퀴놀린-3-카복실산, 1-사이클로프로필-6-플루오로-1,4-디하이드로-4-옥소-7-[6-(5,6,7,8-테트라하이드로-1,6-나프티리딘)]-퀴놀린-3-카복실산, 9-플루오로-2,3-디하이드로-3-메틸-7-옥소-10-[6-(5,6,7,8-테트라하이드로-1,6-나프티리딘)]-7H-피리도[1,2,3-de]-1,4-벤즈옥사진-6-카복실산, 9-플루오로-2,3-디하이드로-3-메틸-7-옥소-[6-(5,6,7,8-테트라하이드로-1,6-나프티리딘)]-7H-피리도[1,2,3-de]-1,4-벤즈옥사진-6-카복실산, 6-플루오로-1-메틸-1,4-디하이드로-4-옥소-7-[6-(5,6,7,8-테트라하이드로-1,6-나프티리딘)]-퀴놀린-3-카복실산, 6-플루오로-1,4-디하이드로-4-옥소-7-[6-(5,6,7,8-테트라하이드로-1,6-나프티리딘)]-퀴놀린-3-카복실산, 6-플루오로-1-(4-플루오로페닐)-1,4-디하이드로-4-옥소-7-[6-(5,6,7,8-테트라하이드로-1,6-나프티리딘)]-퀴놀린-3-카복실산 또는 6-플루오로-1-(-플루오로페닐)-1,4-디하이드로-4-옥소-7-[6-(5,6,7,8-테트라하이드로-1,6-나프티리딘)]-퀴놀린-3-카복실산 또는 염기 염.
  8. 제1항에 따른 화합물을 약제학적으로 허용되는 담체와 혼합하여 포함하는 항균제 조성물.
  9. 항균제로서 사용하기 위한 의약을 제조하기 위해서 제1항 내지 제7항의 어느한항에서 청구된 바와 같은 일반식(Ⅰ) 화합물인 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019880016841A 1987-12-18 1988-12-17 헤테로사이클릭-치환된 퀴놀린 카복실산 KR900008568B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US1987/003412 WO1989005643A1 (en) 1987-12-18 1987-12-18 Heterocyclic-substituted quinoline-carboxylic acids
USPCT/8703412 1987-12-18
USPCT/US87/03412 1987-12-18

Publications (2)

Publication Number Publication Date
KR890009925A true KR890009925A (ko) 1989-08-04
KR900008568B1 KR900008568B1 (ko) 1990-11-24

Family

ID=22202722

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880016841A KR900008568B1 (ko) 1987-12-18 1988-12-17 헤테로사이클릭-치환된 퀴놀린 카복실산

Country Status (18)

Country Link
US (1) US5037834A (ko)
EP (1) EP0321191B1 (ko)
JP (1) JPH0725757B2 (ko)
KR (1) KR900008568B1 (ko)
AT (1) ATE113599T1 (ko)
AU (1) AU600188B2 (ko)
DE (1) DE3852010T2 (ko)
DK (1) DK699788A (ko)
ES (1) ES2061695T3 (ko)
FI (1) FI90239C (ko)
IE (1) IE65732B1 (ko)
IL (1) IL88664A (ko)
MY (1) MY104072A (ko)
NO (1) NO178149C (ko)
NZ (1) NZ227357A (ko)
PT (1) PT89222B (ko)
WO (1) WO1989005643A1 (ko)
ZA (1) ZA889395B (ko)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0251308B1 (de) * 1986-07-04 1990-11-22 Chemie Linz Gesellschaft m.b.H. 4-Chinolon-3-carbonsäurederivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Präparate
US5093515A (en) * 1987-08-14 1992-03-03 Asahi Glass Company Ltd. Fluorinated benzoyl compounds
EP0303291B1 (en) * 1987-08-14 1995-04-26 Asahi Glass Company Ltd. Fluorinated benzoyl compounds
US5214051A (en) * 1989-08-01 1993-05-25 Pfizer Inc. Thiazolyl and oxazolyl[5,4-c]piperidyl-substituted quinolone-carboxylic acid and related analogs thereof having antibacterial properties are disclosed
KR910009330B1 (ko) * 1989-10-23 1991-11-11 재단법인 한국화학연구소 항균작용을 갖는 퀴놀린계 화합물과 그의 제조방법
KR910009333B1 (ko) * 1989-10-23 1991-11-11 재단법인 한국화학연구소 항균작용을 갖는 퀴놀린계 화합물과 그의 제조방법
DE4121214A1 (de) * 1991-06-27 1993-01-14 Bayer Ag 7-azaisoindolinyl-chinolon- und -naphthyridoncarbonsaeure-derivate
DE4342186A1 (de) * 1993-12-10 1995-06-14 Bayer Ag Eintopfverfahren zur Herstellung von 3-Chinoloncarbonsäurederivaten
DE19652239A1 (de) 1996-12-16 1998-06-18 Bayer Ag Verwendung von 7-(2-Oxa-5,8-diazabicyclo[4.3.0]non-8-yl)-chinolon- und -naphthyridoncarbonsäure-Derivaten zur Therapie von Helicobacter-pylori-Infektionen und den damit assoziierten gastroduodenalen Erkrankungen
US6608081B2 (en) 1999-08-12 2003-08-19 Ortho-Mcneil Pharmaceutical, Inc. Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods
US6855385B2 (en) * 2000-05-31 2005-02-15 Ttm Advanced Circuits, Inc. PCB support plate for PCB via fill
CN1250544C (zh) * 2001-02-07 2006-04-12 奥索-麦克尼尔药品公司 吡啶并芳基苯基噁唑烷酮抗菌剂和相关组合物及方法
AU2003263455A1 (en) * 2002-09-26 2004-04-19 Pfizer Inc. Pyrazole amides for treating hiv infections
CL2004000553A1 (es) * 2003-03-20 2005-02-04 Actelion Pharmaceuticals Ltd Uso de compuestos derivados de guanidina como antagonistas del receptor de neuropeptido ff; compuestos derivados de guanidina; procedimientos de preparacion; y composicion farmaceutica que los comprende.
GB0610804D0 (en) * 2006-05-31 2006-07-12 Portela & Ca Sa New crystal forms
PL2054416T3 (pl) * 2006-08-04 2011-05-31 Merz Pharma Gmbh & Co Kgaa Podstawione pirazolopirymidyny, sposób ich wytwarzania oraz ich zastosowanie w medycynie
JP2011506315A (ja) * 2007-12-05 2011-03-03 バイアル−ポルテラ アンド シーエー，エス．エー． 新たな塩、及び結晶形
TWI583680B (zh) * 2011-08-31 2017-05-21 大塚製藥股份有限公司 喹啉酮化合物
EP3700521B1 (en) * 2017-10-29 2024-06-12 China Medical University Use of adam9 inhibitor compound and composition including adam9 inhibitor compound

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE418966B (sv) * 1974-02-18 1981-07-06 Haessle Ab Analogiforfarande for framstellning av foreningar med magsyrasekretionsinhiberande verkan
JPS53141286A (en) * 1977-05-16 1978-12-08 Kyorin Seiyaku Kk Novel substituted quinolinecarboxylic acid
JPS5746986A (en) * 1980-09-02 1982-03-17 Dai Ichi Seiyaku Co Ltd Pyrido(1,2,3-de)(1,4)benzoxazine derivative
US4665079A (en) * 1984-02-17 1987-05-12 Warner-Lambert Company Antibacterial agents
IE55898B1 (en) * 1982-09-09 1991-02-14 Warner Lambert Co Antibacterial agents
JPS59128383A (ja) * 1982-12-29 1984-07-24 Kanebo Ltd 新規キノリンカルボン酸誘導体および該化合物を有効成分とする抗菌剤
JPS59204194A (ja) * 1983-05-09 1984-11-19 Hokuriku Seiyaku Co Ltd ７−ジアザビシクロアルカン置換−６，８−ジフオロ−４−オキソ−１，４−ジヒドロキノリン−３−カルボン酸誘導体
GB8333798D0 (en) * 1983-12-19 1984-01-25 Fujisawa Pharmaceutical Co Quinolone compounds
US4571396A (en) * 1984-04-16 1986-02-18 Warner-Lambert Company Antibacterial agents
US4636506A (en) * 1984-12-06 1987-01-13 Pfizer, Inc. 7-heterocyclic-1,4-dihydroquinolones
US4657913A (en) * 1985-04-18 1987-04-14 Warner-Lambert Company Trifluoro- quinoline -3- carboxylic acids and their use as anti-bacterial agents
DE3519286A1 (de) * 1985-05-30 1986-12-04 Bayer Ag, 5090 Leverkusen 7-azolyl-1-cyclopropyl-1,4-dihydro-4-oxo-3- chinolincarbonsaeuren und -1,8-naphthyridin-3-carbonsaeuren, verfahren zu ihrer herstellung sowie diese enthaltende antibakterielle mittel
IN166416B (ko) * 1985-09-18 1990-05-05 Pfizer

Also Published As

Publication number Publication date
FI893883A0 (fi) 1989-08-17
JPH0725757B2 (ja) 1995-03-22
PT89222B (pt) 1994-11-30
DE3852010D1 (de) 1994-12-08
ES2061695T3 (es) 1994-12-16
ATE113599T1 (de) 1994-11-15
ZA889395B (en) 1990-08-29
FI90239C (fi) 1994-01-10
AU600188B2 (en) 1990-08-02
DK699788A (da) 1989-08-11
IE883763L (en) 1989-06-18
IL88664A0 (en) 1989-07-31
EP0321191B1 (en) 1994-11-02
NO178149B (no) 1995-10-23
AU2698788A (en) 1989-06-22
FI90239B (fi) 1993-09-30
KR900008568B1 (ko) 1990-11-24
NO893305L (no) 1989-10-17
US5037834A (en) 1991-08-06
JPH01211587A (ja) 1989-08-24
IL88664A (en) 1993-08-18
EP0321191A2 (en) 1989-06-21
FI893883A (fi) 1989-08-17
PT89222A (pt) 1989-12-29
DK699788D0 (da) 1988-12-16
MY104072A (en) 1993-11-30
DE3852010T2 (de) 1995-03-09
WO1989005643A1 (en) 1989-06-29
IE65732B1 (en) 1995-11-15
NO178149C (no) 1996-01-31
NO893305D0 (no) 1989-08-17
EP0321191A3 (en) 1991-02-27
NZ227357A (en) 1991-04-26

Similar Documents

Publication Publication Date Title
KR890009925A (ko) 헤테로사이클릭-치환된 퀴놀린 카복실산
JP4515260B2 (ja) アミノシクロヘキセンキノリンおよび抗菌活性を有するそのアザアイソステリック類似体
FI83872B (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara 7-(diaza-eller azabicykloalkyl)-6-fluor-4-oxo-3 -kinolin- eller 1,8-naftyridin-3-karboxylsyror.
KR880012593A (ko) 5-치환 퀴놀론- 및 나프티리돈 카르복실산 유도체
PE20061442A1 (es) Heterociclicos como agonistas del receptor de acido nicotinico para el tratamiento de dislipidemia
KR900003152A (ko) 스피로 화합물
DE50014553D1 (de) Verwendung von Chinolon- und Chinolizinon-Derivaten als Chemotherapeutika
PT89352B (pt) Processo para a preparacao de derivados dos acidos 7-(1-azetidinil)-1,4-dihidro-4-oxoquinoleina-3-carboxilicos e de composicoes farmaceuticas que os contem
PT95642A (pt) Processo para a preparacao de compostos de quinolona e de composicoes farmaceuticas que os contem
KR860008163A (ko) 항균제인 퀴놀린-3- 카복실산의 개량된 제법
KR970704694A (ko) 항미생물 화합물의 제조방법(process for making antimicrobial compounds)
DK174929B1 (da) Fremgangsmåde til fremstilling af quinolincarboxylsyrer eller derivater deraf
KR900015733A (ko) 항-사람 면역결핍증 바이러스 조성물
AP9901532A0 (en) 2-Methoxyphenylpiperazine derivatives.
KR900014380A (ko) 피리돈카르복실산의 아제티딘 유도체, 그의 제조방법 및 의약품으로 응용
RO115261B1 (ro) Derivati de acid chinolon- si naftiridoncarboxilic si procedeu pentru prepararea acestora
KR930021633A (ko) 항균 활성을 갖는 피리돈카르복시산의 신규한 아제티딘 유도체
JPH06192262A (ja) ７−（アミノメチル−オキサ−７−アザ−ビシクロ［３．３．０］オクト−７−イル）キノロンカルボン酸および７−（アミノメチル−オキサ−７−アザ−ビシクロ［３．３．０］オクト−７−イル）ナフチリドンカルボン酸誘導体
KR920006345A (ko) 신규한 퀴놀론 카르복실산 유도체
US5214051A (en) Thiazolyl and oxazolyl[5,4-c]piperidyl-substituted quinolone-carboxylic acid and related analogs thereof having antibacterial properties are disclosed
JPH01165584A (ja) 新規な１，８−ナフチリジン誘導体
KR920008164B1 (ko) 항균작용을 갖는 퀴놀린계 유도체와 그의 제조방법
TH6558B (th) สารประกอบสไพโร
SK283994B6 (sk) Antibakteriálne prostriedky obsahujúce N-oxidy nasýtených dusík obsahujúcich heterocyklov substituovaných chinolónkarboxylovými alebo naftyridónkarboxylovými kyselinami, účiné látky, spôsob ich výroby a ich použitie
KR100332527B1 (ko) 피리돈카르본산유도체또는이것의염및그제조방법

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 19961102

Year of fee payment: 7

LAPS Lapse due to unpaid annual fee